New Launch15 May 2026, 10:31 pm
Fredun Pharma Launches Cellular Longevity Platform 'Daulcél'
AI Summary
Fredun Pharmaceuticals Ltd (BSE: FREDUN) has launched 'DAULCÉL', a premium wellness and longevity-focused brand. This strategic move expands Fredun's presence in preventive healthcare and healthy aging, leveraging NAD+ science. DAULCÉL aims to address the increasing global focus on vitality and long-term healthy living. Fredun reported FY25 revenues of ₹456 Cr, EBITDA of ₹55 Cr, and PAT of ₹21 Cr.
Key Highlights
- Fredun Pharma launches 'DAULCÉL', a premium wellness brand focused on cellular longevity.
- The brand's initial portfolio centers on advanced wellness and healthy lifestyle management.
- This launch marks Fredun's strategic expansion into preventive and lifestyle-oriented healthcare.
- Fredun reported FY25 revenues of ₹456 Cr, EBITDA of ₹55 Cr, and PAT of ₹21 Cr.
- DAULCÉL introduces premium NAD+ based wellness offerings in India.